Limits...
Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Cheng X, Gan W, Zhang G, Li X, Guo H - BMC Urol (2016)

Bottom Line: Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children.Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.

ABSTRACT

Background: Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2 RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a comprehensive assessment on them.

Methods: MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.

Results: A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66-9.34). However, incidence of distant metastases (OR = 0.34, 95 % CI = 0.12-1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14-1.91), tumor stage (OR = 0.85, 95 % CI = 0.34-2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05-4.34) between male and female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67-15.72) in adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38-3.72) was observed. In addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13-7.84) and lymphatic metastases (OR = 1.00, 95 % CI = 0.07-13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20-19.03) between children and adults were comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).

Conclusions: Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

No MeSH data available.


Related in: MedlinePlus

PRISMA Flow Diagram of study selection for Meta- analysis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC4940698&req=5

Fig1: PRISMA Flow Diagram of study selection for Meta- analysis

Mentions: As shown in Fig. 1, 15 studies [4, 10–23] with 147 subjects met the inclusion criteria. All of the enrolled studies were retrospective, in which 2 of them provided all the clinical parameters in different gender while the other gave part of these parameters, as shown in Table 1. None of study provided detailed information about OS in comparison of different age while other clinical parameters were shown in Table 2. The number of studies in the pooled group of gender-related incidence in adults were ≥ 10, as well as patients of all ages, publication bias of the groups were described as visual assessment of a funnel plot in Fig. 2.Fig. 1


Clinical characteristics of XP11.2 translocation/TFE3 gene fusion renal cell carcinoma: a systematic review and meta-analysis of observational studies.

Cheng X, Gan W, Zhang G, Li X, Guo H - BMC Urol (2016)

PRISMA Flow Diagram of study selection for Meta- analysis
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC4940698&req=5

Fig1: PRISMA Flow Diagram of study selection for Meta- analysis
Mentions: As shown in Fig. 1, 15 studies [4, 10–23] with 147 subjects met the inclusion criteria. All of the enrolled studies were retrospective, in which 2 of them provided all the clinical parameters in different gender while the other gave part of these parameters, as shown in Table 1. None of study provided detailed information about OS in comparison of different age while other clinical parameters were shown in Table 2. The number of studies in the pooled group of gender-related incidence in adults were ≥ 10, as well as patients of all ages, publication bias of the groups were described as visual assessment of a funnel plot in Fig. 2.Fig. 1

Bottom Line: Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children.Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

View Article: PubMed Central - PubMed

Affiliation: Department of Urology, Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School, No. 321 Zhongshan Road, Nanjing, 210008, Jiangsu Province, China.

ABSTRACT

Background: Renal cell carcinoma (RCC) associated with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC) is a rare subtype of RCC which is firstly described as a distinct entity in 2004 so that clinical characteristics of Xp11.2 RCC in different gender and age are unknown. The purpose of systematic review and meta-analysis is to provide a comprehensive assessment on them.

Methods: MEDLINE, EMBASE and Cochrane databases were searched for studies which evaluate the clinical characteristics of Xp11.2 RCC. The literature published between July 2004 and May 2014 was searched.

Results: A total of 15 studies with 147 participants were included. The meta-analysis demonstrated that number of patients of all age in female was higher than in male with pooled OR of 3.93(95 % CI = 1.66-9.34). However, incidence of distant metastases (OR = 0.34, 95 % CI = 0.12-1.57) and lymphatic metastases (OR = 0.51, 95 % CI = 0.14-1.91), tumor stage (OR = 0.85, 95 % CI = 0.34-2.15) and overall survival (OS) (OR = 0.46, 95 % CI = 0.05-4.34) between male and female were comparable. Incidence in female was higher than in male with pooled OR of 5.13(95 % CI = 1.67-15.72) in adults, while in children no gender-related predominance (OR = 1.19, 95 % CI = 0.38-3.72) was observed. In addition, incidence of distant metastases (OR = 1.00, 95 % CI = 0.13-7.84) and lymphatic metastases (OR = 1.00, 95 % CI = 0.07-13.67) and tumor stage (OR = 1.94, 95 % CI = 0.20-19.03) between children and adults were comparable. Survival curves presented comparable outcomes between male and female (P = 0.707) as well as between children and adults (P = 0.383).

Conclusions: Female patients with Xp11.2 RCC in adults exhibit a high incidence compared to male, but not in children. Comparable clinical characteristics including incidence of distant and lymphatic metastases, tumor stage and prognosis is presented between male and female as well as between children and adults.

No MeSH data available.


Related in: MedlinePlus